Advertisement

REGN7075 + Libtayo leads to anti-tumor responses in MSS colorectal cancer in dose-escalation portion of phase I/II study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

An ongoing phase I/II study evaluating Regeneron Pharmaceuticals’ first-in-class costimulatory bispecific antibody, REGN7075 (EGFRxCD28), in combination with Libtayo (cemiplimab) in patients with advanced solid tumors showed positive new results. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

Advertisement
Advertisement